Factors such as advanced stage at diagnosis [3,4], high tumor grade [4], negative hormone receptors [4], HER-2 amplification [4], tumor subtype [3], and age [3] are linked to higher mortality rates. This evidence concerns the gene ERBB2 and neoplasm.